Inhibikase therapeutics inc
Webb10 apr. 2024 · Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor to treat Parkinson’s disease and gastrointestinal tract. Webb21 apr. 2024 · The latest Tweets from Inhibikase Therapeutics (@inhibikase). Inhibikase (Nasdaq: $IKT) is developing disease …
Inhibikase therapeutics inc
Did you know?
Webb29 mars 2024 · Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor … Webb13 apr. 2024 · A high-level overview of Inhibikase Therapeutics, Inc. (IKT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
WebbInhibikase Therapeutics är specialiserade inom bioteknik. Bolaget bedriver forskning och utveckling inom hjärnsjukdomar. Exempel på specialistområden är behandling av Parkinsons sjukdom (PS). Bolagets produktkandidater inkluderar IkT-148009. Bolaget grundades 2008 och har sitt huvudkontor i Atlanta, Georgia Till bolagets hemsida Webb10 apr. 2024 · Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. It operates through RAMP™ Drug...
Webb3 apr. 2024 · News auf Englisch zu INHIBIKASE THERAPEUTICS, INC. 03.04. Inhibikase Therapeutics Reports Full Year 2024 Financial Results and Highlights Recent .. AQ. 31.03. INHIBIKASE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condit.. AQ. Webb16 apr. 2024 · Inhibikase Therapeutics, Inc. Study Details Tabular View No Results Posted Disclaimer How to Read a Study Record Study Description Go to Brief Summary: This study investigates the safety and tolerability of drug IkT-148009 in healthy elderly volunteers (55 to 70 years old). It also looks at the movement of IkT-148009 in the body.
Webb23 mars 2024 · BOSTON and ATLANTA, March 23, 2024 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the …
Webb30 sep. 2024 · Inhibikase Therapeutics Inc. is offering 2,272,727 common shares at a price of between $10 and $12 in its IPO. The company, which applied to list its shares on the Nasdaq Capital Market under the IKT symbol, granted the underwriter an option to buy up to an additional 340,909 common shares in the transaction. boer goats exporter to indiaWebb23 mars 2024 · BOSTON and ATLANTA , March 23, 2024 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the … boer goats for sale craigslistWebb8 apr. 2024 · Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2024 Earnings Call Transcript April 3, 2024 Operator: Good morning and welcome to the Inhibikase Fourth … boer goat sale in californiaWebb9 apr. 2024 · 2w. Inhibikase will report financial results for the fourth quarter and full-year ended December 31, 2024 on Friday, March 31, 2024, after the close of U.S. markets. … boer goats for sale australiaWebbInhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify … boer goats breeding seasonWebbInhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases. global investment holdings turkeyWebb28 mars 2024 · Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The Company's product candidates include IkT-148009, IkT-001Pro and IKT-01427. global investment competitiveness gic